Fotemustine: Revision history

From Glioblastoma Treatments
Jump to navigationJump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

12 November 2024

30 March 2024

  • curprev 20:4520:45, 30 March 2024Lazy talk contribs 2,165 bytes +2,165 Created page with "{{TreatmentInfo |drug_name=Fotemustine |FDA_approval=Available in Europe, not FDA-approved in the United States for GBM |used_for=Recurrent Glioblastoma Multiforme (GBM) after the standard Stupp protocol treatment |clinical_trial_phase=Varied, with multiple studies evaluating efficacy and optimal scheduling |common_side_effects=Not specified, typical of nitrosoureas may include myelosuppression, nausea, and liver enzyme elevation |OS_without=Not specified |OS_with=Not sp..."